Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias...

Area of Science:

• Cardiology
• Endocrinology
• Preventive Medicine

Background:

• Atherosclerotic cardiovascular disease (ASCVD) is a leading global cause of mortality.
• Dyslipidemia is a significant modifiable risk factor for ASCVD.
• Effective management of dyslipidemia is crucial across various clinical settings.

Purpose of the Study:

• To present the 2023 guidelines from the Hellenic Atherosclerosis Society for ASCVD prevention and management.
• To provide updated recommendations on lipid disorder assessment and treatment.
• To address specific challenges in managing dyslipidemia in diverse patient groups.

Main Methods:

• Review and synthesis of current evidence on ASCVD risk assessment.
• Evaluation of laboratory diagnostics for dyslipidemias.
• Analysis of novel and established lipid-lowering pharmacotherapies.
• Consideration of treatment strategies for specific patient cohorts and conditions.

Main Results:

• Guidelines emphasize comprehensive ASCVD risk evaluation.
• Recommendations include updated laboratory assessments for dyslipidemias.
• Discussion covers new lipid-lowering drugs and management in special populations (women, elderly, FH, ACS, HF, stroke, CKD, diabetes, autoimmune diseases, NAFLD).
• Statin intolerance is addressed with management strategies.

Conclusions:

• The guidelines provide a framework for optimizing ASCVD prevention and treatment.
• Holistic management of dyslipidemia, considering individual patient profiles, is advocated.
• These recommendations aim to reduce the global burden of ASCVD.